Donafenib
Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option.
Overview
Zelgen's donafenib was approved by the NMPA in June 2021 for first-line unresectable hepatocellular carcinoma on the ZGDH3 trial (668 patients: median overall survival 12.1 versus 10.3 months with sorafenib, hazard ratio 0.83; Journal of Clinical Oncology 2021), the first drug to beat sorafenib on survival in this setting. Radioiodine-refractory differentiated thyroid cancer followed in 2022. A modest gain, but a first for a Chinese company and a model of incremental chemistry (deuteration) turned into an approval.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2021 | First-line unresectable hepatocellular carcinoma (ZGDH3) |
| China | 2022 | Radioiodine-refractory differentiated thyroid cancer |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Donafenib" OR ABSTRACT:"Donafenib" OR TITLE:"Zepsun" OR ABSTRACT:"Zepsun" OR TITLE:"CM4307" OR ABSTRACT:"CM4307") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Donafenib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductRivoceranib (apatinib)
Shares Shukui Qin, VEGF angiogenesis, Anti-angiogenic therapy, VEGF / VEGFR and the tag china.
- ProductAnlotinib
Shares VEGF angiogenesis, Anti-angiogenic therapy, VEGF / VEGFR, Thyroid cancer and the tag china.
- ProductIcotinib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors and the tag china.
- TrialALTER 0303
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag china.
- TrialORIENT-32
Shares Anti-angiogenic therapy, Hepatocellular carcinoma and the tag china.
- ProductGarsorasib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors and the tag china.
- ProductFurmonertinib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors and the tag china.
- ProductSavolitinib
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors and the tag china.